BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 20555360)

  • 1. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
    Hombach A; Hombach AA; Abken H
    Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.
    Sharifzadeh Z; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Jamnani FR; Moghimi SM
    Cancer Lett; 2013 Jul; 334(2):237-44. PubMed ID: 22902507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z
    Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells.
    Heuser C; Hombach A; Lösch C; Manista K; Abken H
    Gene Ther; 2003 Aug; 10(17):1408-19. PubMed ID: 12900755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition.
    Hombach A; Heuser C; Gerken M; Fischer B; Lewalter K; Diehl V; Pohl C; Abken H
    Gene Ther; 2000 Jun; 7(12):1067-75. PubMed ID: 10871757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
    Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
    Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.
    Chmielewski M; Hombach AA; Abken H
    Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
    Chmielewski M; Kopecky C; Hombach AA; Abken H
    Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.
    Riet T; Holzinger A; Dörrie J; Schaft N; Schuler G; Abken H
    Methods Mol Biol; 2013; 969():187-201. PubMed ID: 23296935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC
    J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy.
    Jonnalagadda M; Mardiros A; Urak R; Wang X; Hoffman LJ; Bernanke A; Chang WC; Bretzlaff W; Starr R; Priceman S; Ostberg JR; Forman SJ; Brown CE
    Mol Ther; 2015 Apr; 23(4):757-68. PubMed ID: 25366031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptors for T-cell based therapy.
    Cheadle EJ; Sheard V; Hombach AA; Chmielewski M; Riet T; Berrevoets C; Schooten E; Lamers C; Abken H; Debets R; Gilham DE
    Methods Mol Biol; 2012; 907():645-66. PubMed ID: 22907378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells.
    D'Aloia MM; Caratelli S; Palumbo C; Battella S; Arriga R; Lauro D; Palmieri G; Sconocchia G; Alimandi M
    Cytotherapy; 2016 Feb; 18(2):278-90. PubMed ID: 26705740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.
    Bollino D; Webb TJ
    Transl Res; 2017 Sep; 187():32-43. PubMed ID: 28651074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
    Eshhar Z
    Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
    Pameijer CR; Navanjo A; Meechoovet B; Wagner JR; Aguilar B; Wright CL; Chang WC; Brown CE; Jensen MC
    Cancer Gene Ther; 2007 Jan; 14(1):91-7. PubMed ID: 17024231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors.
    Corrales-Aguilar E; Trilling M; Reinhard H; Mercé-Maldonado E; Widera M; Schaal H; Zimmermann A; Mandelboim O; Hengel H
    J Immunol Methods; 2013 Jan; 387(1-2):21-35. PubMed ID: 23023090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
    Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
    Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional mapping of the Fc gamma RII binding site on human IgG1 by synthetic peptides.
    Medgyesi D; Uray K; Sallai K; Hudecz F; Koncz G; Abramson J; Pecht I; Sármay G; Gergely J
    Eur J Immunol; 2004 Apr; 34(4):1127-35. PubMed ID: 15048724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.